- Q4 Revenue Growth: Net sales rose 4.3% YoY to $105.1 million in Q4 2025.
- Full-Year EBITDA Margin: Adjusted EBITDA margin was 22.2% ($93.9 million) for 2025.
- Professional Channel Expansion: Professional sales surged 18.9% YoY to $36.8 million in Q4.
- 2026 Guidance: Net sales projected at -2% to +3% YoY, with adjusted EBITDA margin of 21-22%.
- SG&A Stability: Adjusted SG&A increased $40.8 million YoY in 2025 but expected to remain flat in 2026.
Segment Performance and Strategic Shifts
The professional channel saw an 18.9% year-over-year increase in sales for the fourth quarter, driven by innovation and strong participation in global holiday events. In contrast, specialty retail declined 14.5% year over year due to the company's strategic pivot towards professional partners. Direct-to-consumer sales increased 6.6% year over year, with the company successfully capturing demand around key shopping events. According to Catherine Dunleavy, "We deliberately shifted international volume towards the professional channel as a primary growth engine."
Guidance for 2026 and Key Initiatives
Olaplex expects net sales in 2026 to be in the range of approximately -2% to +3% versus fiscal year 2025. The company is focusing on energizing its hero products, fueling science-based innovation, and expanding its diversified go-to-market model. Adjusted EBITDA margin is expected to be between 21% to 22%. Analysts estimate next year's revenue growth at 2.8%, indicating a relatively stable outlook.
Valuation Metrics and Investment Considerations
With a Price-to-Sales Ratio of 2.31 and an EV/EBITDA of 8.77, Olaplex's valuation appears reasonable considering its growth prospects. However, the negative ROE of -1.05% and a low ROIC of 0.5% indicate room for improvement in terms of profitability. As the company continues to execute its transformation plan, investors will be watching for progress in these areas.